Operating through 119 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”), an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 320,000 TMS treatments to over 9,000 patients struggling with depression.
June 17, 2020 – Toronto, ON –
GREENBROOK TMS TO HOLD VIRTUAL ANNUAL MEETING OF SHAREHOLDERS ON JUNE 29
May 21, 2020 – Toronto, ON –
GREENBROOK TMS COMPLETES C$15 MILLION EQUITY OFFERING
May 12, 2020 – Toronto, ON –
GREENBROOK TMS REPORTS FIRST QUARTER FINANCIAL RESULTS